In The News

Factors Associated With Improved Glycemic Control Following Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 2 Diabetes Uncontrolled With Bolus-Basal Insulin Regimens: An Analysis From the OpT2mise Randomized Trial

April 4, 2017. This analysis investigated factors associated with A1C decreases in patients receiving continuous subcutaneous insulin infusion (CSII) as part of the OpT2mise randomized trial. Patients with type 2 diabetes (T2D) and A1C levels >8% following multiple daily injection (MDI) optimization were randomized to receive CSII (n=168) or MDI (n=163) for 6 months. Investigators found that CSII produced a significantly greater reduction in A1C versus MDI; this treatment difference was more pronounced in patients with higher baseline A1C.

The LixiLan-L Trial: Consistent Findings in Glycemic Control, Body Weight, and Hypoglycemia With iGlarLixi Vs Insulin Glargine Across Baseline A1C, Body Mass Index, and Diabetes Duration

April 6, 2017. This exploratory analysis was conducted to determine the impact of patient baseline characteristics on outcomes observed in the LixiLan-L randomized open-label trial (N=736). This 30-week trial evaluated the efficacy and safety of iGlarLixi (insulin glargine 100 U [iGlar]) plus lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D). To be included in the study, patients were required to be inadequately controlled on a regimen of basal insulin alone or in combination with 1 or2 oral glucose-lowering drugs.

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients With Type 2 Diabetes Within Blood Glucose Target Ranges

March 2017. This analysis assessed glycemic fluctuations and day-to-day blood glucose variability in patients treated with IDegLira compared with either insulin degludec (IDeg) or liraglutide alone. Investigators analyzed data from 2 randomized trials in patients with type 2 diabetes (T2D); in particular, 9-point self-monitored blood glucose (SMBG) profiles and continuous glucose monitoring (CGM) data from a patient subset. Patients treated with IDegLira were more likely to have SMBG values in target ranges for pre- and postprandial values and for the full 9-point profile (P 

Diabetic Retinopathy: A Position Statement by the American Diabetes Association

March 2017. The American Diabetes Association has updated its Position Statement on diabetic retinopathy for the first time since 2002. The update focuses on improvements in diabetic retinopathy assessment and treatment options, including optical coherence tomography to assess retinal thickness and intraretinal pathology and wide-field fundus photography to reveal clinically silent microvascular lesions. Improvements in medications and devices for systemic diabetes therapy are also discussed.

3 Years of Liraglutide vs Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals With Prediabetes

February 22, 2017. This randomized, controlled, double-blind trial evaluated the proportion of patients with prediabetes and obesity/overweight treated with liraglutide 3.0 mg vs placebo over a 3-year period to determine time to diabetes onset. Patients (N=2,254) from 191 clinical research sites were randomized 2:1; all were assigned to caloric restriction and increased physical activity. Fifty percent of patients completed the full study; patients who withdrew were not followed after discontinuation.

Safety and Efficacy of IDegLira Titrated Once Weekly vs Twice Weekly in Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

March 3, 2017. This open-label trial evaluated the impact of IDegLira (combined insulin degludec and the glucagon-like peptide-1 inhibitor liraglutide) once or twice weekly in insulin-naïve adults with type 2 diabetes inadequately controlled on metformin ± pioglitazone. A total of 420 patients were randomized to this 32-week non-inferiority trial. IDegLira was titrated either once or twice weekly based on mean pre-breakfast plasma glucose readings. With once-weekly titration, mean A1C decreased from 8.2% to 6.1%; reductions for twice-weekly titration were from 8.1% to 6.0%.

Diabetic Retinopathy: A Position Statement by the American Diabetes Association

March 2017. The American Diabetes Association (ADA) has released a position statement on diabetic retinopathy. This is an update of the ADA’s 2002 position statement.

FDA Approves Combined Dapagliflozin/Saxagliptin for Adults With Type 2 Diabetes

February 28, 2017. The US Food and Drug Administration has approved a once-daily formulation of dapagliflozin 10 mg and saxagliptin 5 mg (trade name Qtern). Qtern provides dual antihyperglycemic therapy to patients with type 2 diabetes by combining a sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor in a single daily tablet.

FDA Approves Label Update for Dulaglutide to Include Use in Combination With Basal Insulin

February 8, 2017. The US Food and Drug Administration has approved a label update for the glucagon-like-1 (GLP-1) receptor agonist dulaglutide. Dulaglutide is now approved for use in combination with basal insulin in adults with type 2 diabetes. This update makes dulaglutide the first GLP-1 receptor agonist indicated for combination use with mealtime insulin or basal insulin.

Chronic Liraglutide Therapy Induces an Enhanced Endogenous Glucagon-like Peptide-1 Secretory Response in Early Type 2 Diabetes

January 2017. This study evaluated the impact of chronic liraglutide therapy on endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Fifty-one patients with type 2 diabetes (mean duration, 2.6 years, +/- 1.9 years) were randomized for 48 weeks to subcutaneous liraglutide or placebo. Patients received an oral glucose tolerance test (OGTT) every 12 weeks, with GLP-1 and GIP area under the curve (AUC) measured at 0, 30, 60, 90, and 120 minutes. No between-group differences were observed for AUC GIP.

Pages